NCI-2024-07005

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Advanced or Metastatic

Urothelial Carcinoma or Other Solid Tumors

This is a Phase 1a/1b study testing a drug called LY4052031, which is an antibody-drug conjugate designed to target a protein called Nectin-4 on cancer cells. The study is for people with advanced or metastatic urothelial carcinoma (a type of bladder cancer) or other solid tumors (cancers that form in organs or tissues). The study will test how safe the drug is, how the body processes it, and how well it works to treat these cancers. It is designed to find the best dose of the drug and learn how it can help fight cancer.

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

antibody-drug conjugate: ADCs have two parts: an antibody that targets cancer cells and a chemotherapy drug that kills cancer cells.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06465069

Clinical Trial Site: Sinai

To see all available clinical trials click here.